Constructing co-stimulation to boost TCR therapy

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-05-30 DOI:10.1038/s43018-024-00746-9

Julia Höbart, Jürgen Ruland

引用次数: 0

Abstract

T cell receptor (TCR)-engineered T cells offer great promise for targeting tumor antigens in cancer therapy. A synthetic fusion protein termed 80BB, which can simultaneously activate the CD28 and 4-1BB co-stimulatory pathways, is now shown to enhance overall functionality of therapeutic TCR/CD3-dependent T cells in an antigen-agnostic manner.

Abstract Image

查看原文本刊更多论文

构建协同刺激，促进 TCR 治疗。

在癌症治疗中，T细胞受体（TCR）工程T细胞为靶向肿瘤抗原提供了巨大前景。一种名为 80BB 的合成融合蛋白能同时激活 CD28 和 4-1BB 协同刺激途径，现已证明它能以抗原识别的方式增强治疗性 TCR/CD3 依赖性 T 细胞的整体功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.